European Peptide Society

• Venue Name: The Wellcome Trust Conference Centre
• Venue Address:
  • Cambridge
  • UK
• Start Date: March 30, 2010
• End Date: March 31, 2010
• Description:

  
  Introduction

  Organised by avakado media, this conference takes place at The Wellcome Trust Conference Centre, Cambridge, UK from Tuesday, March 30 to Wednesday, March 31, 2010. The conference features leading researchers and experts from the various fields of peptide therapeutics development presenting the latest scientific and technological knowledge in these rapidly advancing areas of life sciences. The applications of peptide chemistry from synthesis through purification and analytics, to bioactivity testing in biotechnology, biomedical and other applications from analytical to industrial scales are presented.

  ---

  Click here to register today. Academic* delegate rate now available!

  ---

  Delegates who will benefit from attending the conference are senior R&D scientists, managers and decision makers from pharmaceutical and biotechnology companies looking to develop new peptide analytics, therapeutics and diagnostics and efficiently and economically manufacture new peptide products.

  * Academic rate applies to postdoctoral researchers and faculty working in universities, technology colleges or other educational institutions

  Please note if you are arriving at the conference centre by car you MUST display a parking permit please Click Here to download (this also includes a location map).

  
  Top-quality speaker line-up

  Here are some of the top-quality speakers you will meet when you register to attend The Peptide Conference 2010:

  Chris Ullman is Chief Scientific Officer at Isogenica Ltd, a small biotech company that is using its CIS display technology to develop therapeutic peptides and proteins.

  He has been at Isogenica since 2002, where he has been involved in the development of CIS display. Prior to joining Isogenica, he was Team Leader for Gendaq Ltd (later acquired by Sangamo Biosciences Inc), developing customised transcription factors using engineered zinc finger DNA binding proteins to target any DNA sequence. This technology was spun out from Sir Aaron Klug’s Laboratory at the LMB, Cambridge, UK.

  Chris will present a paper describing new display technology for the selection of therapeutic proteins.
   

  ---

  Don Wellings is the owner and founder of SpheriTech Ltd based in Runcorn, Cheshire, UK.

  He has been performing laboratory- to process-scale peptide synthesis for almost 30 years and has a track record spanning careers in ICI, Zeneca and Avecia. More recently, Don headed the Solid Phase Organic Chemistry group within Avecia before leaving in 2004 to join Polymer Laboratories. In 2006, he founded Chromatide Ltd, a company specialising in contract synthesis and purification. SpheriTech was founded in 2009 to provide a consultancy-based business and laboratory-based resource for contract R&D.

  Don’s paper reviews modern methods for solid phase peptide synthesis.
   

  ---

  Katja Arndt received her PhD in Biochemistry under the supervision of Professor Andreas Plückthun, University of Zurich and Professor Tom Alber, University of California, Berkeley.

  With acceptance into the Emmy-Noether Excellence programme of the German Research Foundation (DFG) in 2003, she became head of the Protein Engineering in Biosystems group in the Department of Biology, University of Freiburg, Germany. In 2008, she became a principle investigator in the BIOSS excellence cluster and was appointed as Junior Fellow in the School of Life Sciences (LIFENET) of the Freiburg Institute for Advanced Studies (FRIAS).

  Her paper describes the development of photo-switchable peptides to inhibit protein-protein interactions.
   

  ---

  Having received his BSc in Chemistry from Durham University, Graham Cotton received his PhD from the University of Edinburgh working with Professor Bob Ramage in the field of synthetic peptide and protein chemistry and therapeutics.

  After continuing these studies as a post-doctoral worker at Edinburgh University, he moved in 1996 to Rockefeller University, where he spent four years as a Postdoctoral Fellow in the laboratory of Professor Tom Muir, developing novel protein engineering technologies and their application to studying cellular signalling. He then returned to the UK to continue this interdisciplinary research with Amersham Biosciences, establishing new programmes at the chemistry/biology interface. In 2002, he moved to Almac Sciences Scotland (formerly Albachem), initially as Senior Research Scientist. He is now the company’s R&D Group Leader.

  His paper is on recombinant protein hydrazides, which are versatile derivatives for the site-specific labelling of proteins. 

  ---

  Ingrid Marchal studied biochemistry and molecular biology at the University of Lille, where she worked on the glycosylation of proteins in insect cells.

  After completing her PhD, she started her industrial career by contributing to the creation of a start-up bioinformatics company in Paris. She subsequently joined a company specialised in protein engineering with responsibility for business development and marketing. Since 2006, she has been working with Protéus, a company specialised in the development of proteins and protein-based processes for health care and industrial applications.

  Her paper describes how to evaluate immunogenicity in the development of therapeutic peptides.
   

  ---

  
  Conference Programme

  The programme for The Peptide Conference 2010 is as follows:

  
  Tuesday, March 30, 2010

  Morning Session 1: Peptides in Drug Discovery

  09:00-09:40
  "Peptides as research tools in drug discovery"
  Dr Laurent Caron, Core Peptide Technology Manager,
  Cambridge Research Biochemicals

  09:40-10:20
  "CIS display: an in-vitro display technology for the selection of therapeutic proteins"
  Dr Chris Ullman, CSO, Isogenica Ltd

  10:20-11:00
  "Next-generation peptide microarrays and screening tools"
  Dr Volker Stadler, CEO, PEPperPRINT GmbH

  11:00-11:40
  Coffee Break

  Morning Session 2: Peptide Synthesis
  Chaired by Dr Bob Sheppard, pioneer of Fmoc based solid phase peptide synthesis chemistry

  11:40-12:20
  "Modern concepts for solid phase peptide synthesis"
  Dr Donald A. Wellings, CEO, SpheriTech Ltd

  12:20-13:00
  "Chemical or recombinant peptide synthesis: which way to go? Route selection in the development of industrial processes"
  Dr Oleg Werbitzky, Director Innovation and Future Technologies, Lonza AG

  13:00-14:00
  Lunch

  Afternoon Session 1: Peptide Synthesis
  Chaired by Dr Bob Sheppard

  14:00-14:40
  "Recent trends in large-scale solid phase peptide synthesis: longer and synthetically challenging targets"
  Dr Eric Atherton, Scientific Advisor, CBL Biopharma (CBL Patras)

  14:40-15:20
  "Synthetic peptide manufacturing: improving solvent use for green, safe and cost-efficient processes"
  Dr Geoffroy Sommen, Process Optimization Project Leader, Lonza Braine SA

  15:20-16:00
  Coffee Break

  Afternoon Session 2: Peptide Therapeutics

  16:00-16:40
  "Design and development of therapeutic peptides for autoimmune diseases"
  Dr Keith F. Martin, CEO, Apitope

  16:40-17:20
  "Development of therapeutic peptides"
  Dr Santhana Krishnan, Dr Reddy’s Laboratories Limited

  17:20-18:00
  "Development of photo-switchable peptides to inhibit protein-protein interactions"
  Dr Katja Arndt, Department of Biology, University of Freiburg

  19:00-21:00
  Networking Reception

   
  Wednesday, March 31, 2010

  Morning Session 1: Peptide Therapeutics

  09:00-09:40
  "The novel peptide derivative of FKBPL, ALD-001, demonstrates potent anti-angiogenic and anti-metastatic activity"
  Dr Martin O’Rourke, Team Leader Biology, Almac Discovery

  09:40-10:20
  "Optimisation of antimicrobial peptides targeting bacteria and viruses"
  Dr David Ulaeto, Department of Biomedical Sciences, Dstl Porton Down

  10:20-11:00
  "Clinical development of an oral formulation of recombinant salmon calcitonin"
  Dr Nozer Mehta, VP of Research and Development, Unigene Laboratories

  11:00-11:40
  Coffee Break

  Morning Session 2: Labeling and Characterisation

  11:40-12:20
  "Recombinant protein hydrazides, versatile derivatives for the site-specific labelling of proteins: application to the site-specific PEGylation of interferons"
  Dr Graham Cotton, R&D Group Leader, Almac Sciences (Scotland) Ltd

  12:20-13:00
  "Light scattering for protein and peptide characterisation"
  Dr Hanna Jankevics, Product Technical Specialist - Biophysical Characterization, Malvern Instruments Ltd

  13:00-14:00
  Lunch

  Afternoon Session 1: Peptide Drug Properties

  14:00-14:40
  "Immunogenicity evaluation for the development of therapeutic peptides"
  Dr Ingrid Marchal-Gerez, Business Development Manager, Protéus

  14:40-15:20
  "Cell-penetrating peptides: enhancing the delivery of oligonucleotides and peptides by conjugation"
  Dr Mike Gait, MRC Programme Leader, MRC Laboratory of Molecular Biology

  15:20-16:00
  Coffee Break

  Afternoon Session 2: Peptide Drug Properties

  16:00-16:40
  "Peptide conjugation, formulation and delivery challenges"
  Dr Mimoun Ayoub, Vice President, Strategic Development, Peptisyntha, Member of Solvay Group

  16:40-17:20
  "PepIDENT - non-random protein-specific biopeptide libraries and multi-protein synthetic peptidomics"
  Dr Hubert Bernauer, CEO, ATG:biosynthetics

   

• Meeting Website URL: http://www.avakado.eu/dev/Biofine/Peptide/Conference/2010

CONTACT DETAILS:

• Contact: Tom Mulligan
• Contact Address:
• Contact Email: tom@avakado.eu